[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cabaletta Bio Inc (CABA)

Cabaletta Bio Inc (CABA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 448,401
  • Shares Outstanding, K 163,055
  • Annual Sales, $ 0 K
  • Annual Income, $ -167,860 K
  • EBIT $ -179 M
  • EBITDA $ -167 M
  • 60-Month Beta 3.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.92

Options Overview Details

View History
  • Implied Volatility 133.69% (+32.47%)
  • Historical Volatility 49.50%
  • IV Percentile 57%
  • IV Rank 21.27%
  • IV High 362.13% on 09/04/25
  • IV Low 71.95% on 07/10/26
  • Expected Move (DTE 6) 0.26 (9.27%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 272
  • Volume Avg (30-Day) 971
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 83,484
  • Open Int (30-Day) 81,753
  • Expected Range 2.50 to 3.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.35
  • Number of Estimates 3
  • High Estimate $-0.34
  • Low Estimate $-0.36
  • Prior Year $-0.44
  • Growth Rate Est. (year over year) +20.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.59 +6.18%
on 08/03/26
2.89 -4.84%
on 08/13/26
+0.08 (+3.00%)
since 07/14/26
3-Month
2.59 +6.18%
on 08/03/26
4.08 -32.60%
on 05/27/26
-0.86 (-23.82%)
since 05/14/26
52-Week
1.40 +96.43%
on 08/29/25
4.23 -34.99%
on 05/06/26
+1.10 (+66.67%)
since 08/14/25

Most Recent Stories

More News
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile myositis Phase 1/2 data expected to be submitted with BLA...

CABA : 2.75 (+1.48%)
Cabaletta Bio Keeps Narrowing Losses but Still Has No Revenue to Show

Barchart Research What to Expect from CABA Earnings CABA Generated August 12, 2026 Current Price $2.85 EPS Estimate $$-0.37 Consensus Rating Moderate Buy Average Move 12.42% Cabaletta Bio Keeps Narrowing...

CABA : 2.75 (+1.48%)
Cabaletta Bio's Preconditioning-Free Data Could Redefine What Investors Expect From Autoimmune Cell Therapy

Barchart Research What to Expect from CABA Earnings CABA Generated August 5, 2026 Current Price $2.71 EPS Estimate $$-0.37 Consensus Rating Moderate Buy Average Move 12.42% Cabaletta Bio's Preconditioning-Free...

CABA : 2.75 (+1.48%)
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest...

CABA : 2.75 (+1.48%)
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV ® study presented today at ASGCT 2026 Annual Meeting along with initial...

CABA : 2.75 (+1.48%)
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4...

CABA : 2.75 (+1.48%)
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative...

CABA : 2.75 (+1.48%)
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry  Initial...

CABA : 2.75 (+1.48%)
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically...

CABA : 2.75 (+1.48%)
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET™ clinical...

CABA : 2.75 (+1.48%)

Business Summary

Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are...

See More

Key Turning Points

3rd Resistance Point 2.93
2nd Resistance Point 2.85
1st Resistance Point 2.80
Last Price 2.75
1st Support Level 2.67
2nd Support Level 2.59
3rd Support Level 2.54

See More

52-Week High 4.23
Fibonacci 61.8% 3.15
Fibonacci 50% 2.82
Last Price 2.75
Fibonacci 38.2% 2.48
52-Week Low 1.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.